These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 25593184)

  • 1. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
    Flynn RL; Cox KE; Jeitany M; Wakimoto H; Bryll AR; Ganem NJ; Bersani F; Pineda JR; Suvà ML; Benes CH; Haber DA; Boussin FD; Zou L
    Science; 2015 Jan; 347(6219):273-7. PubMed ID: 25593184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells.
    Eid R; Demattei MV; Episkopou H; Augé-Gouillou C; Decottignies A; Grandin N; Charbonneau M
    Mol Cell Biol; 2015 Aug; 35(16):2818-30. PubMed ID: 26055325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
    Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
    PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
    Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
    J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
    Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
    Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
    Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
    PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
    Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hRad21 overexpresses and localizes to the ALT-associated promyelocytic leukemia body in ALT cells.
    Zhao B; Wang ZJ; Yi BQ; Ma HC; Xu HM
    Cancer Biol Ther; 2010 Jun; 9(12):978-83. PubMed ID: 20364118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres.
    Temime-Smaali N; Guittat L; Wenner T; Bayart E; Douarre C; Gomez D; Giraud-Panis MJ; Londono-Vallejo A; Gilson E; Amor-Guéret M; Riou JF
    EMBO J; 2008 May; 27(10):1513-24. PubMed ID: 18418389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres.
    Pan X; Drosopoulos WC; Sethi L; Madireddy A; Schildkraut CL; Zhang D
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5940-E5949. PubMed ID: 28673972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
    Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
    PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere maintenance by telomerase and by recombination can coexist in human cells.
    Cerone MA; Londono-Vallejo JA; Bacchetti S
    Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells.
    Arora R; Lee Y; Wischnewski H; Brun CM; Schwarz T; Azzalin CM
    Nat Commun; 2014 Oct; 5():5220. PubMed ID: 25330849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus.
    Kamranvar SA; Chen X; Masucci MG
    Oncogene; 2013 Dec; 32(49):5522-30. PubMed ID: 23708666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
    Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
    de Nonneville A; Salas S; Bertucci F; Sobinoff AP; Adélaïde J; Guille A; Finetti P; Noble JR; Churikov D; Chaffanet M; Lavit E; Pickett HA; Bouvier C; Birnbaum D; Reddel RR; Géli V
    EMBO Mol Med; 2022 Oct; 14(10):e15859. PubMed ID: 35920001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
    Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
    Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The macroH2A1.2 histone variant links ATRX loss to alternative telomere lengthening.
    Kim J; Sun C; Tran AD; Chin PJ; Ruiz PD; Wang K; Gibbons RJ; Gamble MJ; Liu Y; Oberdoerffer P
    Nat Struct Mol Biol; 2019 Mar; 26(3):213-219. PubMed ID: 30833786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.